Copeland Capital Management LLC Decreases Stock Holdings in Zoetis Inc. $ZTS

Copeland Capital Management LLC decreased its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 0.4% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 81,251 shares of the company’s stock after selling 351 shares during the quarter. Copeland Capital Management LLC’s holdings in Zoetis were worth $12,671,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of ZTS. Brighton Jones LLC raised its stake in Zoetis by 180.4% during the fourth quarter. Brighton Jones LLC now owns 4,629 shares of the company’s stock valued at $754,000 after purchasing an additional 2,978 shares in the last quarter. Merit Financial Group LLC raised its stake in Zoetis by 62.3% during the first quarter. Merit Financial Group LLC now owns 12,178 shares of the company’s stock valued at $2,005,000 after purchasing an additional 4,676 shares in the last quarter. Secure Asset Management LLC raised its stake in Zoetis by 3.6% during the first quarter. Secure Asset Management LLC now owns 2,380 shares of the company’s stock valued at $392,000 after purchasing an additional 83 shares in the last quarter. Thurston Springer Miller Herd & Titak Inc. raised its stake in Zoetis by 75.9% during the first quarter. Thurston Springer Miller Herd & Titak Inc. now owns 11,546 shares of the company’s stock valued at $1,901,000 after purchasing an additional 4,981 shares in the last quarter. Finally, Thrive Wealth Management LLC raised its stake in shares of Zoetis by 27.9% in the first quarter. Thrive Wealth Management LLC now owns 6,647 shares of the company’s stock valued at $1,094,000 after acquiring an additional 1,450 shares during the period. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Zoetis Trading Down 0.3%

NYSE ZTS opened at $146.46 on Friday. The company’s 50-day moving average price is $149.89 and its 200-day moving average price is $155.26. The company has a current ratio of 1.76, a quick ratio of 1.04 and a debt-to-equity ratio of 1.05. The stock has a market cap of $64.91 billion, a PE ratio of 25.21, a PEG ratio of 2.36 and a beta of 0.90. Zoetis Inc. has a 12 month low of $139.34 and a 12 month high of $196.55.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Tuesday, August 5th. The company reported $1.76 EPS for the quarter, topping analysts’ consensus estimates of $1.62 by $0.14. The firm had revenue of $2.46 billion for the quarter, compared to analysts’ expectations of $2.41 billion. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The business’s revenue for the quarter was up 4.2% on a year-over-year basis. During the same period in the prior year, the business posted $1.56 earnings per share. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Equities research analysts forecast that Zoetis Inc. will post 6.07 earnings per share for the current year.

Analyst Upgrades and Downgrades

ZTS has been the topic of several recent analyst reports. Leerink Partners downgraded shares of Zoetis from an “outperform” rating to a “market perform” rating and reduced their target price for the company from $180.00 to $155.00 in a research note on Thursday, July 17th. Piper Sandler increased their target price on shares of Zoetis from $210.00 to $215.00 and gave the company an “overweight” rating in a research note on Monday, August 11th. Leerink Partnrs downgraded shares of Zoetis from a “strong-buy” rating to a “hold” rating in a research note on Thursday, July 17th. Argus reissued a “buy” rating and issued a $190.00 target price on shares of Zoetis in a research note on Tuesday, September 9th. Finally, Stifel Nicolaus downgraded shares of Zoetis from a “buy” rating to a “hold” rating and reduced their target price for the company from $165.00 to $160.00 in a research note on Wednesday, June 18th. Five equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat.com, Zoetis has a consensus rating of “Moderate Buy” and an average price target of $200.88.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.